Table 3.
Distribution of erythromycin, clindamycin and tetracycline resistance rates and macrolide resistance phenotypes in 1071 invasive and non-invasive isolates of Group B streptococci within different patient groups.
| Patients group | Invasive GBS isolates (n = 80) N (%) |
Noninvasive GBS isolates (n = 991) N (%) |
||||||
|---|---|---|---|---|---|---|---|---|
| Antibiotic resistance | EOD | LOD | Adults | ∑ | Pregnant women—asymptomatic colonisation | Non-pregnant adults—urogenital infections | ∑ | |
| Erythromycin | 12 (29.3) | 6 (31.6) | 5 (25) | 23 (28.8) | 233 (26.6) | 30 (26.3) | 263 (26.5) | |
| Phenotype | ||||||||
| cMLS | 7 (58.3) | 4 (66.7) | 3 (60) | 14 (60.9) | 145 (62.2) | 15 (50) | 160 (60.8) | |
| iMLS | 3 (25) | 1 (16.7) | – | 4 (14.4) | 47 (20.2) | 12 (40) | 59 (22.4) | |
| M | 2 (16.7) | 1 (16.7) | 2 (40) | 5 (21.7) | 41 (17.6) | 3 (10) | 44 (16.7) | |
| Clindamycin | 10 (24.4) | 5 (26.3) | 3 (15) | 18 (22.5) | 192 (21.9) | 27 (23.7) | 219 (22.1) | |
| Tetracycline | 36 (87.8) | 13 (68.4) | 16 (80) | 65 (81.3) | 754 (86) | 94 (82.5) | 848 (85.6) | |
| ∑ | 41 (100) | 19 (100) | 20 (100) | 80 (100) | 877 (100) | 114 (100) | 991 (100) | |
EOD early-onset disease, LOD late-onset disease, GBS Group B streptococcus.